YPYiru Pan

Yiru Pan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yiru Pan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Anguo Wu

    Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation Key Laboratory of Medical Electrophysiology of Ministry of Education, School of Pharmacy Southwest Medical University Luzhou China

    3 shared publications
  • Da-Lian Qin

    Sichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Department of Cardiology, the Affiliated Hospital of Southwest Medical University and Key Laboratory of Medical Electrophysiology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China

    2 shared publications
  • Jianming Wu

    School of Basic Medical Sciences Southwest Medical University Luzhou China

    2 shared publications
  • Jing Wei

    Department of Ophthalmology The Affiliated Hospital of Southwest Medical University Luzhou China

    2 shared publications
  • Lu Yu

    Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, School of Pharmacy, School of Basic Medical Sciences, Southwest Medical University, Luzhou, China

    2 shared publications
  • Xiao-Gang Zhou

    School of Pharmacy, Southwest Medical University, Luzhou, China

    2 shared publications

Latest Publications

  • Prosapogenin CP4 exacerbates mitophagy to induce apoptosis via AMPK-mTOR and PINK1/Parkin pathways in A549 cells

    by Yiru Pan, Jing Wei, Dalian Qin, Xiaogang Zhou, Fei Gao, Lu Yu, Chi Feng, Jianing Mi, Jianming Wu, Betty Yuen Kwan Law, et al.


  • Open Access

    Elaiophylin Elicits Robust Anti-Tumor Responses via Apoptosis Induction and Attenuation of Proliferation, Migration, Invasion, and Angiogenesis in Pancreatic Cancer Cells

    by Lufen Huang, Yufeng Liu, Yiru Pan, Chao Liu, Huijie Gao, Qiang Ren, Jianan Wang, Huiyun Wang, Yuntao Zhang, Anguo Wu

    Pancreatic cancer remains a formidable challenge in oncology due to its aggressive nature and limited treatment options. In this study, we investigate the potential therapeutic efficacy of elaiophylin, a novel compound, in targeting BxPC-3 and PANC-1 pancreatic cancer cells. We comprehensively explore elaiophylin’s impact on apoptosis induction, proliferation inhibition, migration suppression, invasion attenuation, and angiogenesis inhibition, key processes contributing to cancer progression and metastasis. The results demonstrate that elaiophylin exerts potent pro-apoptotic effects, inducing a substantial increase in apoptotic cells. Additionally, elaiophylin significantly inhibits proliferation, migration, and invasion of BxPC-3 and PANC-1 cells. Furthermore, elaiophylin exhibits remarkable anti-angiogenic activity, effectively disrupting tube formation in HUVECs. Moreover, elaiophylin significantly inhibits the Wnt/β-Catenin signaling pathway. Our findings collectively demonstrate the multifaceted potential of elaiophylin as a promising therapeutic agent against pancreatic cancer via inhibition of the Wnt/β-Catenin signaling pathway. By targeting diverse cellular processes crucial for cancer progression, elaiophylin emerges as a prospective candidate for future targeted therapies. Further investigation of the in vivo efficacy of elaiophylin is warranted, potentially paving the way for novel and effective treatment approaches in pancreatic cancer management.


  • Open Access

    Targeting Nrf2‐Mediated Oxidative Stress Response in Traumatic Brain Injury: Therapeutic Perspectives of Phytochemicals

    by An-Guo Wu, Yuan-Yuan Yong, Yi-Ru Pan, Li Zhang, Jian-Ming Wu, Yue Zhang, Yong Tang, Jing Wei, Lu Yu, Betty Yuen-Kwan Law, et al.

    Traumatic brain injury (TBI), known as mechanical damage to the brain, impairs the normal function of the brain seriously. Its clinical symptoms manifest as behavioral impairment, cognitive decline, communication difficulties, etc. The pathophysiological mechanisms of TBI are complex and involve inflammatory response, oxidative stress, mitochondrial dysfunction, blood‐brain barrier (BBB) disruption, and so on. Among them, oxidative stress, one of the important mechanisms, occurs at the beginning and accompanies the whole process of TBI. Most importantly, excessive oxidative stress causes BBB disruption and brings injury to lipids, proteins, and DNA, leading to the generation of lipid peroxidation, damage of nuclear and mitochondrial DNA, neuronal apoptosis, and neuroinflammatory response. Transcription factor NF‐E2 related factor 2 (Nrf2), a basic leucine zipper protein, plays an important role in the regulation of antioxidant proteins, such as oxygenase‐1(HO‐1), NAD(P)H Quinone Dehydrogenase 1 (NQO1), and glutathione peroxidase (GPx), to protect against oxidative stress, neuroinflammation, and neuronal apoptosis. Recently, emerging evidence indicated the knockout (KO) of Nrf2 aggravates the pathology of TBI, while the treatment of Nrf2 activators inhibits neuronal apoptosis and neuroinflammatory responses via reducing oxidative damage. Phytochemicals from fruits, vegetables, grains, and other medical herbs have been demonstrated to activate the Nrf2 signaling pathway and exert neuroprotective effects in TBI. In this review, we emphasized the contributive role of oxidative stress in the pathology of TBI and the protective mechanism of the Nrf2‐mediated oxidative stress response for the treatment of TBI. In addition, we summarized the research advances of phytochemicals, including polyphenols, terpenoids, natural pigments, and otherwise, in the activation of Nrf2 signaling and their potential therapies for TBI. Although there is still limited clinical application evidence for these natural Nrf2 activators, we believe that the combinational use of phytochemicals such as Nrf2 activators with gene and stem cell therapy will be a promising therapeutic strategy for TBI in the future.